Effect of the H2-receptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients.
Depression and anxiety were measured during the course of a double-blind, placebo-controlled trial of the histamine H2-receptor antagonist, ranitidine (150 mg twice daily), in patients suffering from duodenal ulcer but free of systemic disease. There were 25 patients in the ranitidine group (mean age: 33.2 years) and 28 in the placebo group (mean age: 37.2 years). In both groups there was a highly significant and progressive decrease in depression and anxiety scores over the 4 weeks of treatment. There were no instances of mental confusion. In our group of otherwise physically healthy patients, ranitidine appeared to be free of neuropsychiatric complications.
D000328:Adult; D001007:Anxiety / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D011899:Ranitidine / Q000009:adverse effects* / Q000627:therapeutic use
D011899:Ranitidine